PRRT2 and cancer: Given that PKC mutations in cancer generally are not only loss of function, but also dominant-negative, gaining a better understanding of cancer-associated PKCγ mutations will be critically important to applying therapies that will produce beneficial outcomes in cancer patients harboring these mutations (Figure 2).